StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.28−0.07 (-5.19%)

Close on Nov 20, 2026Market cap $30.47MP/E –Yield –

Kalaris Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Kalaris Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$38.57M. For fiscal 2025 it was -$38.57M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$38.57M–
FY2021Dec 31, 2021-$106.35M–
FY2020Dec 31, 2020-$61.05M–
FY2019Dec 31, 2019-$20.49M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$7.07M–
Q4 FY2021Dec 31, 2021-$27.70M–
Q3 FY2021Sep 30, 2021-$36.47M–
Q2 FY2021Jun 30, 2021-$23.18M–
Q1 FY2021Mar 31, 2021-$19.00M–
Q4 FY2019Dec 31, 2019-$8.99M–
Q3 FY2019Sep 30, 2019-$6.40M–

More Kalaris Therapeutics figures

See a number that looks wrong?